Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients

被引:23
作者
Rogers, Christin C. [1 ]
Johnson, Scott R. [2 ]
Mandelbrot, Didier A. [3 ]
Pavlakis, Martha [3 ]
Horwedel, Timothy [1 ]
Karp, Seth J. [2 ]
Egbuna, Ogo [3 ]
Rodrigue, James R. [4 ]
Chudzinski, Robyn E. [3 ]
Goldfarb-Rumyantzev, Alexander S. [3 ]
Hanto, Douglas W. [2 ]
Curry, Michael P. [3 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pharm, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA
[3] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[4] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA
关键词
calcineurin inhibitor withdrawal; calcineurin inhibitor nephrotoxicty; liver transplantation; sirolimus; CALCINEURIN INHIBITOR; COST-EFFECTIVENESS; IMMUNOSUPPRESSION; RAPAMYCIN; NEPHROTOXICITY; MONOTHERAPY; DYSFUNCTION; THERAPY; FAILURE; DISEASE;
D O I
10.1111/j.1399-0012.2009.01040.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The long-term use of calcineurin inhibitors (CNI) leads to renal dysfunction in many liver transplant (LT) recipients. The purpose of this analysis is to evaluate renal function in patients converted from CNI to sirolimus (SRL). From May 2002-November 2006, 137 LT were performed in 125 patients, 72 of which were converted to SRL. Evaluation of SRL conversion was stratified by early conversion (< 90 d from LT) (EC) vs. late conversion (LC). Renal function was evaluated using the six-point modification of diet in renal disease formula (estimated glomerular filtration rate [eGFR]). Forty-two patients on SRL and 40 on CNI had at least three months of follow-up and are included in the eGFR evaluation. At all time points after conversion, the EC group demonstrated a significantly higher mean eGFR than those in the LC group. A significant improvement in eGFR was seen within the EC group when comparing eGFR at time of conversion to eGFR at three, six, nine, and 12 months after conversion and last follow-up. The only improvement in the LC group was from conversion to the three-month time point. We conclude that EC to SRL results in a profound improvement in eGFR that begins at three months and is sustained beyond one yr.
引用
收藏
页码:887 / 896
页数:10
相关论文
共 28 条
[1]   Influence of hepatitis C on renal function after liver transplantation [J].
Asfandiyar, S. ;
Abouljoud, M. ;
Kim, D. ;
Brown, K. ;
Yoshida, A. ;
Arenas, J. ;
Sherbondy, M. ;
Divine, G. ;
Moonka, D. .
TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) :3643-3645
[2]   Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis:: Analysis of the underlying mechanisms [J].
Biecker, E ;
De Gottardi, A ;
Neef, M ;
Unternährer, M ;
Schneider, V ;
Ledermann, M ;
Sägesser, H ;
Shaw, S ;
Reichen, J .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) :952-961
[3]   Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation [J].
Campbell, Mical S. ;
Rai, Jitha ;
Kozin, Elliott ;
Bloom, Roy D. ;
Markmann, James F. ;
Olthoff, Kim M. ;
Shaked, Abraham ;
Reddy, K. Rajender .
CLINICAL TRANSPLANTATION, 2007, 21 (03) :377-384
[4]   Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent [J].
Cotterell, AH ;
Fisher, RA ;
King, AL ;
Gehr, TWB ;
Dawson, S ;
Sterling, RK ;
Stravitz, RT ;
Luketic, VA ;
Sanyal, AJ ;
Shiffman, ML ;
Posner, MP .
CLINICAL TRANSPLANTATION, 2002, 16 :49-51
[5]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[6]   Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus [J].
Fairbanks, KD ;
Eustace, JA ;
Fine, D ;
Thuluvath, PJ .
LIVER TRANSPLANTATION, 2003, 9 (10) :1079-1085
[7]   Chronic renal failure following liver transplantation - A retrospective analysis [J].
Fisher, NC ;
Nightingale, PG ;
Gunson, BK ;
Lipkin, GW ;
Neuberger, JM .
TRANSPLANTATION, 1998, 66 (01) :59-66
[8]   Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs [J].
Flechner, Stuart M. ;
Goldfarb, David ;
Solez, Kim ;
Modlin, Charles S. ;
Mastroianni, Barbara ;
Savas, Kathy ;
Babineau, Denise ;
Kurian, Sunil ;
Salomon, Daniel ;
Novick, Andrew C. ;
Cook, Daniel J. .
TRANSPLANTATION, 2007, 83 (07) :883-892
[9]   End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy - Risk of development and treatment [J].
Gonwa, TA ;
Mai, ML ;
Melton, LB ;
Hays, SR ;
Goldstein, RM ;
Levy, MF ;
Klintmalm, GB .
TRANSPLANTATION, 2001, 72 (12) :1934-1939
[10]   Sirolimus-based immunosuppresive protocol for calcineurin sparing in liver transplantation [J].
Heffron, TG ;
Smallwood, GA ;
Davis, L ;
Martinez, E ;
Stieber, AC .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) :1522-1523